World Health Organization & Merck Group

World Health Organization: The World Health Organization is coordinating the vaccine supply and recommending clinical trials, playing a key role in the global response. Its actions are critical to controlling the outbreak.

Merck Group: Merck Group is the developer of Ervebo, the only approved Ebola vaccine, which is being deployed in the DRC outbreak. Its role is central, and successful cross-protection could expand its market and reputation.

World Health Organization: Coordinating vaccine allocation and clinical trials, but facing uncertainty about vaccine efficacy against the current strain. Its guidance is critical for the response.

Merck Group: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.

World Health Organization: Leading the international response, declaring a PHEIC, recommending vaccine trials, and adding a diagnostic test to its Emergency Use Listing. Its credibility is tied to the success of the response.

Merck Group: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.

World Health Organization: Publicly warned that the policy contradicts decades of evidence and could leave children unprotected. Its stance reinforces international scientific consensus against the order.

Merck Group: As a major MMR manufacturer, it faces potential regulatory and market changes. It stated no scientific evidence supports splitting the vaccine, and it may face pressure to develop separate shots.

World Health Organization: WHO Director-General Tedros warned that progress is fragile without sustained funding, supporting the report's message.

Merck Group: Announced plans to allow generic production of alimatravir, potentially expanding market access.